We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
高シグナルの見出しのみ — マクロイベント、決算、M&A、規制。リスト記事とアナリストのクリックベイトはデフォルトでフィルタ。1時間ごとに更新。
By Deena Beasley LOS ANGELES, May 7 (Reuters) - Gilead Sciences on Thursday posted a higher-than-expected first-quarter profit and raised its outlook for 2026 sales, but said it now expects a loss for
US benchmark equity indexes were lower intraday, while oil prices were moving higher, as investors m
Deal volume in 2026 is far outpacing last year, and is being driven by cancer and autoimmune disease drugs.
Earnings season marches on as investors will hear from big companies including McDonald's and CoreWeave. Data on the U.S. jobs market will also be watched closely, culminating in April nonfarm payroll numbers Friday.
By Karen Roman Oncolytics Biotech Inc. (Nasdaq: ONCY) said it has new data showing the use of pelareorep in metastatic colorectal cancer has a 19.5-month median duration of response compared to […]
Beneath the headline noise of a Q1 2026 beat and raised guidance, the critical insight for Tempus AI lies in a structural tug of war between an accelerating data moat and a currently elevated cost structure. The market is focusing on the 36% year over year top line growth to $348.1 million. The true alpha driver is hidden within the unit economics of the Data and Applications segment. This division is actively shifting the company from a traditional diagnostics provider to a recurring revenue he